At ASCO 2019, many presentations featured recent progress in the breast cancer field. A lot of attention went to biomarkers but also the treatment of triple negative breast cancer, luminal disease, HER2 positive disease as well as agnostic breast cancers subtypes were discussed.
L. Buisseret MD, S. Pommey , B. Allard , S. Garaud , M-A. Bergeron , I. Cousineau , L. Ameye , G. Chouinard , H. Duvillier , M. Paesmans , M.J. Piccart-Gebhart MD, K. Willard-Gallo , C. Sotiriou MD, PhD, J. Stagg
Top
